Is Idexx Laboratories (IDXX) a risky stock?
As of July 21, 2026, Clavix grades Idexx Laboratories (IDXX) A- for risk, a composite score of 81 out of 100 on an A+ to F scale, which puts IDXX in the "low risk" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 21, 2026. Clavix regrades every trading day.
The five risk dimensions behind IDXX's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how IDXX scores on each, as of July 21, 2026.
What's moving IDXX's risk right now
Company-specific signals Clavix flags behind IDXX's current grade, drawn from recent news and filings as of July 21, 2026.
A MarketBeat piece names IDXX as one of three AI-driven medical device stocks that lagged in the first half but could draw buyers if earnings estimates keep improving. IDXX also appeared on two water-stocks screener lists on July 15 and 16.
True North Advisors LLC bought a new 1,411-share position in IDEXX Laboratories during Q1, according to its 13F filing. The position is tiny but points to fresh institutional interest in the stock.
What a A- grade means
On the Clavix A+ to F scale, IDXX's composite of 81 falls in the A band (80–100), read as "low risk." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell IDXX or any security. Grades are risk indicators, not predictions of return. Data may be delayed.